Data / Public companies / Maryland / Pharmaceutical preparations
Pharmaceutical preparations companies in Maryland: 21 that file annual reports with the SEC
21 companies that file annual reports with the SEC have a business address in Maryland and the industry code SIC 2834 (Pharmaceutical preparations), in the SEC Financial Statement Data Sets filed through September 30, 2026. 10 report revenue, a combined $4.81 billion. 5.3% of the 19 that report net income show a profit. The largest by revenue is United Therapeutics Corp ($3.18 billion).
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- 2834SIC code
- 21Companies with an annual report in the data
- 10Companies that report revenue
- $4.81 billionCombined revenue
- $6.2 millionMedian revenue
- 1 of 19 (5.3%)Reported a net profit
- $10.93 billionCombined total assets
- 2Large accelerated filers
- April 15, 2026Newest annual report filed
Largest by revenue
Latest fiscal year, from each company's annual report. Each name links to the company's page.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| United Therapeutics Corp | Silver Spring, MD | $3.18 billion | $1.33 billion | $7.88 billion | 10.6% |
| Emergent Biosolutions Inc. | Gaithersburg, MD | $742.9 million | Not listed | Not listed | -28.8% |
| Supernus Pharmaceuticals, Inc. | Rockville, MD | $719 million | $-38,550,000 | $1.45 billion | 8.6% |
| Macrogenics Inc | Rockville, MD | $149.5 million | $-74,620,000 | $256.8 million | -0.3% |
| Precigen, Inc. | Germantown, MD | $9.7 million | $-250,642,000 | $155.5 million | 146.7% |
| Cartesian Therapeutics, Inc. | Frederick, MD | $2.8 million | $-130,302,000 | $296.4 million | -92.8% |
| Northwest Biotherapeutics Inc | Bethesda, MD | $1.4 million | $-60,162,000 | $81.3 million | -0.3% |
| Orgenesis Inc. | Germantown, MD | $1 million | $-48,165,000 | $1.4 million | 95.3% |
| Bullfrog Ai Holdings, Inc. | Gaithersburg, MD | $116,670 | $-6,498,068 | $2.8 million | Not listed |
| Altimmune, Inc. | Gaithersburg, MD | $41,000 | $-88,093,000 | $279.9 million | 105% |
Companies by size of revenue
Companies that report revenue, by the revenue in their latest annual report.
| Revenue | Companies | Share |
|---|---|---|
| Under $10 million | 6 | 60% |
| $100 million to $1 billion | 3 | 30% |
| $1 billion to $10 billion | 1 | 10% |
Cities with the most companies
By city of the business address.
| City | Companies | Share |
|---|---|---|
| Rockville | 6 | 28.6% |
| Gaithersburg | 4 | 19% |
| Bethesda | 3 | 14.3% |
| Germantown | 3 | 14.3% |
| Baltimore | 1 | 4.8% |
| Beltsville | 1 | 4.8% |
| Frederick | 1 | 4.8% |
| Potomac | 1 | 4.8% |
| Silver Spring | 1 | 4.8% |
Newest annual reports
By the date the company filed its latest annual report with the SEC.
| Company | Filed | Fiscal year ended | Form | Revenue |
|---|---|---|---|---|
| Northwest Biotherapeutics Inc | April 15, 2026 | December 31, 2025 | 10-K | $1.4 million |
| Novabridge Biosciences | April 7, 2026 | December 31, 2025 | 20-F | Not listed |
| Os Therapies Inc | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Shuttle Pharmaceuticals Holdings, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Greater Cannabis Company, Inc. | March 31, 2026 | December 31, 2025 | 10-K | Not listed |
| Sensei Biotherapeutics, Inc. | March 30, 2026 | December 31, 2025 | 10-K | Not listed |
| Gain Therapeutics, Inc. | March 26, 2026 | December 31, 2025 | 10-K | Not listed |
| Orgenesis Inc. | March 26, 2026 | December 31, 2024 | 10-K | $1 million |
| Precigen, Inc. | March 25, 2026 | December 31, 2025 | 10-K | $9.7 million |
| Bullfrog Ai Holdings, Inc. | March 19, 2026 | December 31, 2025 | 10-K | $116,670 |
| Igc Pharma, Inc. | March 18, 2026 | December 31, 2025 | 10-KT | Not listed |
| Barinthus Biotherapeutics PLC. | March 13, 2026 | December 31, 2025 | 10-K | $0 |
Filer category
The SEC's size class for the company when it filed.
| Category | Companies | Share |
|---|---|---|
| Non-accelerated filer | 18 | 85.7% |
| Large accelerated filer | 2 | 9.5% |
| Accelerated filer | 1 | 4.8% |
Updated September 30, 2026. Read from SEC Financial Statement Data Sets (sec.gov). Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.